| Heading: |
Rare Diseases: Medical Treatments |
| Question ID: |
1813042 |
| UIN: |
60246 |
| House: |
Commons |
| Date tabled: |
2025-06-16 |
| Asking Member ID: |
5149 |
| Asking Member display name: |
Amanda Hack
|
| Asking Member handle: |
|
| Asking Member Twitter reference: |
Amanda Hack
|
| Member interest: |
false |
| Question text: |
To ask the Secretary of State for Health and Social Care, what discussions he has had with NICE on feedback from stakeholders on how the impacts on carers are considered in appraisals for rare and ultra-rare conditions. |
| Is named day: |
false |
| Date of holding answer: |
|
| Date answered: |
2025-06-20 |
| Date answer corrected: |
|
| Is holding answer: |
false |
| Is correcting answer: |
false |
| Answering Member ID: |
4444 |
| Answering Member display name: |
Karin Smyth
|
| Answering Member handle: |
karinsmyth
|
| Answering Member Twitter reference: |
@karinsmyth
|
| Correcting Member ID: |
|
| Correcting Member display name: |
|
| Correcting Member handle: |
|
| Correcting Member Twitter reference: |
|
| Answer text: |
In making its recommendations on new medicines, the National Institute for Health and Care Excellence (NICE) takes into account all health-related costs and benefits, including health benefits to carers. It does not, however, take into account wider socie... |
| Original answer text: |
|
| Comparable answer text: |
|
| Answering body ID: |
17 |
| Answering body name: |
Department of Health and Social Care |
| Tweeted: |
true |